Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback